Marshall Wace, LLP Catalyst Biosciences, Inc. Transaction History

Marshall Wace, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.51 - $1.0 $34,478 - $67,605	-67,605 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$0.91 - $4.16 $61,520 - $281,236	67,605 New	67,605 $61,000
Q3 2020 Nov 16, 2020	SELL	$4.22 - $6.04 $59,320 - $84,904	-14,057 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$3.76 - $8.01 $52,854 - $112,596	14,057 New	14,057 $83,000
Q1 2020 May 15, 2020	SELL	$3.5 - $8.51 $439,512 - $1.07 Million	-125,575 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$4.52 - $7.91 $567,599 - $993,298	125,575 New	125,575 $855,000
Q2 2019 Aug 14, 2019	SELL	$7.08 - $10.6 $835,192 - $1.25 Million	-117,965 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$7.67 - $9.96 $2.68 Million - $3.49 Million	-350,032 Reduced 74.79%	117,965 $957,000
Q4 2018 Feb 14, 2019	SELL	$6.59 - $11.28 $531,107 - $909,089	-80,593 Reduced 14.69%	467,997 $3.69 Million
Q3 2018 Nov 14, 2018	SELL	$9.35 - $12.44 $16,474 - $21,919	-1,762 Reduced 0.32%	548,590 $5.91 Million
Q2 2018 Aug 14, 2018	BUY	$9.11 - $28.88 $5.01 Million - $15.9 Million	550,352 New	550,352 $6.42 Million

215

Ticker CBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,477,100
Description
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.